|
|
HAART improves HIV-CMC in addition to systemic measures of HIV infection. H MRS detects improvement of brain injury measured by cerebral metabolites, particularly the glial marker [MI], in patients with early HIV-CMC after HAART. In addi tion, the degree of improvement in clinical severity of HIV-CMC is related to the degree of recovery with [MI]. |
|